Gastroenterology Search

Gastroenterology

Gastroenterology

Home News Diseases Conferences Special Reports

NONALCOHOLIC FATTY LIVER DISEASE

Nonalcoholic fatty liver disease is having excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes.

It is considered as a hepatic manifestation of metabolic syndrome.

Progression of nonalcoholic fatty liver disease is variable.

Nonalcoholic Fatty Liver Disease Drug Information

Drug Information

Essentiale Forte N

phospholipids

Indication: Nutritional support in the management of damaged liver due to chronic liver disease, liver cirrhosis, fatty li...

MIMS Class: Cholagogues, Cholelitholytics & Hepatic Protectors

sanofi-aventis [ DKSH ]

Shine Hepavite

calcium pantothenate + cyanocobalamin + nicotinami...

Indication: Adjuvant treatment of chronic liver disease, liver cirrhosis, fatty liver & intoxication by hepatotoxic su...

MIMS Class: Cholagogues, Cholelitholytics & Hepatic Protectors

Y.S.P. Industries [ Y.S.P. Industries ]

Shine Hepavite Forte

calcium pantothenate + nicotinamide + pyridoxine h...

Indication: Adjuvant treatment of chronic liver diseases, liver cirrhosis, fatty liver & intoxication by hepatotoxic s...

MIMS Class: Cholagogues, Cholelitholytics & Hepatic Protectors

Y.S.P. Industries [ Y.S.P. Industries ]

Simepar

calcium pantothenate + nicotinamide + silymarin + ...

Indication: Toxic & inflammatory liver disorders. Adjuvant in chronic liver disease.

MIMS Class: Cholagogues, Cholelitholytics & Hepatic Protectors

Acino Switzerland [ Mepharm ]

Cefasily

MIMS Class: Cholagogues, Cholelitholytics & Hepatic Protectors

Livolin Forte

MIMS Class: Cholagogues, Cholelitholytics & Hepatic Protectors

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!

High dose comparable to lower doses of ACE inhibitors for heart failure

Jairia Dela Cruz, 16 Sep 2020

In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.